ArticleFrontiers in nutrition2025
The modifying effect of dietary index for gut microbiota on the association between urinary arsenic exposure and bladder cancer risk: a nationwide cohort study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The gut-brain axis in arsenic-induced toxicity: mechanisms, consequences, and therapeutic perspectives.Metabolic brain disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Arsenic exposure is a well-established risk factor for bladder cancer, but substantial individual variability in susceptibility suggests the potential role of effect modifiers. The gut microbiome, which is influenced by diet, may regulate arsenic metabolism and toxicity. The Dietary Index for Gut Microbiota (DIGM) quantifies the potential of diet to foster a beneficial gut ecosystem, yet its role in modifying arsenic-related carcinogenesis remains unclear. This study aimed to investigate the potential interaction between urinary arsenic levels and DIGM on bladder cancer risk. Methods: We conducted a cross-sectional analysis using data from the National Health and Nutrition Examination Survey (NHANES) 2007-2018. Bladder cancer status was obtained through self-reported medical questionnaires. Total urinary arsenic was measured using ICP-DRC-MS, and arsenobetaine was subtracted to estimate toxic inorganic arsenic exposure. DIGM was constructed based on 24-h dietary recall data. Weighted multivariable logistic regression models were used to evaluate associations, and interaction was tested by including a product term (urinary arsenic*DIGM) and assessed on both additive and multiplicative scales. Results: Among 4,889 participants (mean age 47.47 years; 50.34% male), 585 had bladder cancer. After adjusting for covariates, elevated urinary arsenic was associated with increased bladder cancer risk (OR: 2.22, 95% CI: 1.53-3.22). Interaction analysis revealed a significant multiplicative interaction between urinary arsenic and DIGM (P-interaction = 0.022). Stratified analysis showed a strong positive association between urinary arsenic and bladder cancer in participants in the lowest DIGM tertile (OR: 1.95, 95% CI: 1.46-2.61). This association was significantly attenuated and became non-significant in those in the highest DIGM tertile (OR: 1.13, 95% CI: 0.89-1.44). Measures of additive interaction (RERI = 0.47, AP = 0.31) further supported a synergistic effect. Conclusion: Our findings suggest that a diet promoting a healthier gut microbiota, as indicated by a higher DIGM score, may attenuate the association between urinary arsenic exposure and bladder cancer risk. These results indicate that dietary intervention could be a strategic approach to mitigate urinary arsenic-related cancer risk, highlighting the importance of diet-gut-microbiome interactions in environmental carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.